(EMAILWIRE.COM, June 02, 2008 ) Denver, CO - LegalView.com, the most comprehensive resource for everything legal on the Web, recently updated its Levaquin (http://levaquin.legalview.com) practice area after a study found the antibiotic increased the potential for spontaneous tendon rupture among patients. It was discovered that individuals who are taking the prescription medication may be at risk during treatment as well as those who had at one time taken the drug. According to documented reports, patients who took the drug over a year ago may still be at risk for the levaquin side effects (http://levaquin.legalview.com), comprising of tendon rupture.
Levaquin, also known as levofloxacin, is part of a group of antibiotics referred to as the fluoroquinolones. The prescription drug is commonly prescribed to treat a range of bacterial infections such as pneumonia, urinary tract infection, bronchitis, Chlamydia, gonorrhea, prostate infections, and even some skin infections are treated with the drug. Patients who have taken Levaquin are advised to conact an experienced pharmaceutical lawyer in order to better understand the details regarding Levaquin lawsuits (http://levaquin.legalview.com). It may also be possible for patients to become involved with a Levaquin class action (http://levaquin.legalview.com), in which other individuals who have taken the drug and suffered from the serious and severe side effects are all represented seeking compensatory damages.
Additional Levaquin side effects also range from pain and inflammation to diarrhea as well as central nervous system conditions that may be long lasting as well as the tendon ruptures that may require corrective surgery, according to the Levaquin informational site sponsored by Ortho-McNeil-Janssen Pharmaceuticals. To learn more about the serious side effects as well as the potential for being involved in a class action lawsuit, visit http://levaquin.legalview.com/. Also, use the LegalView homepage to navigate to other controversial prescription drug practice areas including the information portals of Chantix, Singulair and Vytorin.
Chantix and Singulair, while both very different medications, have recently found their way into news headlines for similar and deadly side effects that include depression, suicidal thoughts and actions, erratic behavior and moodiness. Chantix is a smoking cessation drug that was released in mid-2006 from Pfizer and was prescribed to nearly 3 million Americans. In late 2007, reports reached the U.S. Food and Drug Administration (FDA) regarding the severe Chantix side effects (http://chantix.legalview.com), which affected at least 400 individuals, who filed reports to the FDA, along with nearly 40 reported suicides of those taking the drug. Singulair, on the other hand, is a prescription drug used to treat asthma and allergies among patients. The Singulair side effects (http://singulair.legalview.com) became apparent to the FDA in March, when reports of suicidal behavior, among adults and children alike, surfaced.
Additionally, Vytorin (http://vytorin.legalview.com) has become a controversial prescription drug due to its alleged inability to effectively treat individuals suffering from artery plaque buildup and high levels of bad cholesterol in the bloodstream, according to a report released in early 2008. Vytorin is often used in combination with Zetia, and both drugs were discovered to be nearly three times more expensive than generic versions while providing less beneficial treatments to patients with this condition.
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.
This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution service, go to http://www.emailwire.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: